Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

• Status: Withdrawn
• Trial end date: 2020-11-07
• Target enrollment: 0
• Participant gender: All

Summary

This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Southern California
• Collaborator: National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Patients scheduled for 90Y radioembolization for HCC as part of their standard of care

Exclusion Criteria:

• Patients who have already received tumor treatment (either systemic or loco-regional such as previous Y90RE, microwave or radiofrequency [RF] ablation or transarterial chemoembolization [TACE])

• Pregnant or nursing

• Known cardiac shunt

• Known pulmonary hypertension

• History of hypersensitivity to Definity (perflutren lipid microsphere) or Lumason

• History of hypersensitivity to iodinated contrast agent

• Cannot consent for himself or herself